Literature DB >> 16364753

Replication-defective viruses as vaccines and vaccine vectors.

Tim Dudek1, David M Knipe.   

Abstract

The classical viral vaccine approaches using inactivated virus or live-attenuated virus have not been successful for some viruses, such as human immunodeficiency virus or herpes simplex virus. Therefore, new types of vaccines are needed to combat these infections. Replication-defective mutant viruses are defective for one or more functions that are essential for viral genome replication or synthesis and assembly of viral particles. These viruses are propagated in complementing cell lines expressing the missing gene product; however, in normal cells, they express viral gene products but do not replicate to form progeny virions. As vaccines, these mutant viruses have advantages of both classical types of viral vaccines in being as safe as inactivated virus but expressing viral antigens inside infected cells so that MHC class I and class II presentation can occur efficiently. Replication-defective viruses have served both as vaccines for the virus itself and as a vector for the expression of heterologous antigens. The potential advantages and disadvantages of these vaccines are discussed as well as contrasting them with single-cycle mutant virus vaccines and replicon/amplicon versions of vaccines. Replication-defective viruses have also served as important probes of the host immune response in helping to define the importance of the first round of infected cells in the host immune response, the mechanisms of activation of innate immune response, and the role of the complement pathway in humoral immune responses to viruses.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16364753     DOI: 10.1016/j.virol.2005.09.020

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  80 in total

1.  Identification and Characterization of a Small-Molecule Rabies Virus Entry Inhibitor.

Authors:  Venice Du Pont; Christoph Wirblich; Jeong-Joong Yoon; Robert M Cox; Matthias J Schnell; Richard K Plemper
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

2.  Towards an effective genital herpes vaccine: past lessons and future prospects.

Authors:  William P Halford
Journal:  Future Virol       Date:  2007-01-01       Impact factor: 1.831

Review 3.  The use of mice lacking type I or both type I and type II interferon responses in research on hemorrhagic fever viruses. Part 2: Vaccine efficacy studies.

Authors:  Marko Zivcec; Christina F Spiropoulou; Jessica R Spengler
Journal:  Antiviral Res       Date:  2020-01-22       Impact factor: 5.970

Review 4.  Optimizing siRNA delivery to the genital mucosa.

Authors:  Joseph A Katakowski; Deborah Palliser
Journal:  Discov Med       Date:  2011-02       Impact factor: 2.970

Review 5.  True grit: programmed necrosis in antiviral host defense, inflammation, and immunogenicity.

Authors:  Edward S Mocarski; William J Kaiser; Devon Livingston-Rosanoff; Jason W Upton; Lisa P Daley-Bauer
Journal:  J Immunol       Date:  2014-03-01       Impact factor: 5.422

Review 6.  Gene Delivery in Neuro-Oncology.

Authors:  Karan Dixit; Priya Kumthekar
Journal:  Curr Oncol Rep       Date:  2017-09-02       Impact factor: 5.075

Review 7.  The challenge of developing a herpes simplex virus 2 vaccine.

Authors:  Lesia K Dropulic; Jeffrey I Cohen
Journal:  Expert Rev Vaccines       Date:  2012-12       Impact factor: 5.217

8.  Characterization of a single-cycle rabies virus-based vaccine vector.

Authors:  Emily A Gomme; Elizabeth J Faul; Phyllis Flomenberg; James P McGettigan; Matthias J Schnell
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

9.  Virus-encoded b7-2 costimulation molecules enhance the protective capacity of a replication-defective herpes simplex virus type 2 vaccine in immunocompetent mice.

Authors:  Sri P Vagvala; Lydia G Thebeau; Saydra R Wilson; Lynda A Morrison
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

Review 10.  Rationalizing the development of live attenuated virus vaccines.

Authors:  Adam S Lauring; Jeremy O Jones; Raul Andino
Journal:  Nat Biotechnol       Date:  2010-06-07       Impact factor: 54.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.